15 May, 2026

This week brought a piece of good news from one of medicine’s toughest corners. Researchers reported early signs that a new drug could help slow pancreatic cancer, a disease known not just for its severity, but for the fewer breakthroughs it has seen compared to other cancers. Treatments have improved slowly, and options remain limited for most patients.

Daraxonrasib, a drug nearing regulatory approval, is the first to substantially extend the lives of patients with pancreatic cancer. The drug targets a genetic mutation that scientists have struggled to treat in the past. In early trials, some patients saw their cancer stabilise or shrink for a time. The results are modest, and researchers are careful not to oversell them. But they point to something new: a way of tackling the disease that hasn’t really worked before, made possible by publicly funded research and private sector development working in tandem.

It is not a cure, and it won’t change outcomes overnight, but for a disease where progress has been slow, even limited success matters. What is encouraging is the direction of travel too. The work builds on years of research that didn’t make headlines, carried out by teams who kept working on problems that others may have written off. So. it shows how better understanding, better tools and patience can open doors that once looked shut.

The takeaway isn’t excitement so much as an acknowledgement that big change can often start quietly, and sometimes, that’s how real progress begins, particularly when everyone involved is open to cross-sector partnerships in pursuit of the same goal.

By Bertie Bateman